ZA200301275B - Antibodies to human IL-1beta. - Google Patents
Antibodies to human IL-1beta. Download PDFInfo
- Publication number
- ZA200301275B ZA200301275B ZA200301275A ZA200301275A ZA200301275B ZA 200301275 B ZA200301275 B ZA 200301275B ZA 200301275 A ZA200301275 A ZA 200301275A ZA 200301275 A ZA200301275 A ZA 200301275A ZA 200301275 B ZA200301275 B ZA 200301275B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino acid
- ser
- acid sequence
- antibody
- human
- Prior art date
Links
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 title claims description 10
- 238000009739 binding Methods 0.000 claims description 105
- 230000027455 binding Effects 0.000 claims description 104
- 102000000589 Interleukin-1 Human genes 0.000 claims description 69
- 108010002352 Interleukin-1 Proteins 0.000 claims description 69
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 69
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 42
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 20
- 108020004705 Codon Proteins 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 102000003810 Interleukin-18 Human genes 0.000 claims description 15
- 108090000171 Interleukin-18 Proteins 0.000 claims description 15
- 230000001404 mediated effect Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 230000000890 antigenic effect Effects 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 11
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 7
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 7
- 102100039065 Interleukin-1 beta Human genes 0.000 claims description 7
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 6
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 229960001838 canakinumab Drugs 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 20
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 241001529936 Murinae Species 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 208000037765 diseases and disorders Diseases 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 5
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- XWOBNBRUDDUEEY-UWVGGRQHSA-N Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XWOBNBRUDDUEEY-UWVGGRQHSA-N 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101001076393 Rattus norvegicus Interleukin-1 beta Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 102000052620 human IL10 Human genes 0.000 description 1
- 102000043959 human IL18 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102220182830 rs886051834 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0020685.4A GB0020685D0 (en) | 2000-08-22 | 2000-08-22 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200301275B true ZA200301275B (en) | 2004-04-02 |
Family
ID=9898090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200301275A ZA200301275B (en) | 2000-08-22 | 2003-02-17 | Antibodies to human IL-1beta. |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US7446175B2 (OSRAM) |
| EP (1) | EP1313769B2 (OSRAM) |
| JP (2) | JP4271936B2 (OSRAM) |
| KR (2) | KR20080056316A (OSRAM) |
| CN (1) | CN100547003C (OSRAM) |
| AR (1) | AR035581A1 (OSRAM) |
| AT (1) | ATE396206T1 (OSRAM) |
| AU (2) | AU9549001A (OSRAM) |
| BE (1) | BE2009C057I2 (OSRAM) |
| BR (1) | BR0113420A (OSRAM) |
| CA (1) | CA2420231C (OSRAM) |
| CY (2) | CY1108779T1 (OSRAM) |
| CZ (1) | CZ304470B6 (OSRAM) |
| DE (2) | DE60134148D1 (OSRAM) |
| DK (1) | DK1313769T4 (OSRAM) |
| EC (1) | ECSP034490A (OSRAM) |
| ES (1) | ES2305110T5 (OSRAM) |
| FR (1) | FR09C0062I2 (OSRAM) |
| GB (1) | GB0020685D0 (OSRAM) |
| HU (2) | HU228159B1 (OSRAM) |
| IL (2) | IL154465A0 (OSRAM) |
| LU (1) | LU91624I2 (OSRAM) |
| MX (1) | MXPA03001590A (OSRAM) |
| MY (1) | MY130248A (OSRAM) |
| NL (1) | NL300427I2 (OSRAM) |
| NO (3) | NO332609B1 (OSRAM) |
| NZ (2) | NZ524199A (OSRAM) |
| PE (1) | PE20020319A1 (OSRAM) |
| PL (1) | PL212480B1 (OSRAM) |
| PT (1) | PT1313769E (OSRAM) |
| RU (1) | RU2286351C2 (OSRAM) |
| SI (1) | SI1313769T2 (OSRAM) |
| SK (1) | SK288089B6 (OSRAM) |
| TW (1) | TWI321568B (OSRAM) |
| WO (1) | WO2002016436A2 (OSRAM) |
| ZA (1) | ZA200301275B (OSRAM) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2426710A1 (en) * | 2000-11-08 | 2002-10-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| DK2213685T3 (en) * | 2002-09-06 | 2014-03-03 | Medarex Llc | Therapeutic anti-IL-1R1 monoclonal antibody |
| US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| CN1780855B (zh) * | 2003-01-24 | 2011-03-30 | 应用分子进化公司 | 人IL-1β拮抗剂 |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| WO2004100987A2 (en) * | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| EP1720893B1 (en) * | 2004-02-26 | 2014-08-13 | Baylor Research Institute | Compositions and methods for the systemic treatment of arthritis |
| AU2006208286A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| AU2012213934B9 (en) * | 2005-01-26 | 2013-07-25 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| GB0509512D0 (en) * | 2005-05-10 | 2005-06-15 | Novartis Ag | Organic compounds |
| JP4931919B2 (ja) * | 2005-06-21 | 2012-05-16 | ゾーマ テクノロジー リミテッド | ＩＬ−１β結合抗体およびその断片 |
| JP2009511545A (ja) * | 2005-10-14 | 2009-03-19 | ノボ・ノルデイスク・エー／エス | Ｉｌ−１インヒビターを使用する糖尿病の治療 |
| CA2898369C (en) * | 2005-10-26 | 2017-06-20 | Novartis Ag | Novel use of il-1beta compounds |
| BRPI0709977A2 (pt) * | 2006-04-14 | 2011-08-02 | Novartis Ag | uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos |
| AU2007333635B2 (en) | 2006-12-20 | 2014-02-20 | Xoma (Us) Llc | Treatment of IL-1-beta related diseases |
| CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| RU2009148597A (ru) | 2007-05-29 | 2011-07-10 | Новартис АГ (CH) | Новые показания к применению при лечении антителами против il-1-бета |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| PT2391650E (pt) * | 2007-12-20 | 2015-01-14 | Xoma Us Llc | Métodos para o tratamento de gota |
| AU2009241589B2 (en) | 2008-04-29 | 2013-10-10 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| AU2009256246B2 (en) | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| DK2293816T3 (da) * | 2008-06-06 | 2013-02-04 | Xoma Technology Ltd | Fremgangsmåder til behandling af reumatoid arthritis |
| CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
| JP2012502059A (ja) | 2008-09-05 | 2012-01-26 | ゾーマ テクノロジー リミテッド | ＩＬ−１β関連疾患を処置または予防するための方法 |
| US20100150864A1 (en) * | 2008-10-20 | 2010-06-17 | Abbott Laboratories, Inc. | Antibodies that bind to il-18 and methods of purifying the same |
| US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| US20130122008A1 (en) * | 2009-05-06 | 2013-05-16 | Novartis Ag | Anti-IL 1- ß Antibody Combination Therapy |
| US8389474B1 (en) * | 2009-07-14 | 2013-03-05 | Alan Anson Wanderer | Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion |
| AR078254A1 (es) * | 2009-09-01 | 2011-10-26 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| MX2012004415A (es) * | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| BR122022001178B1 (pt) | 2009-10-26 | 2022-10-04 | F. Hoffmann-La Roche Ag | Método para a produção de uma imunoglobulina glicosilada e seu uso |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8551487B2 (en) * | 2010-05-07 | 2013-10-08 | Xoma Technology, Ltd. | Methods for the treatment of IL-1β related conditions |
| JP2013537415A (ja) | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| EP2608803A4 (en) | 2010-08-26 | 2014-01-15 | Abbvie Inc | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| WO2012142391A1 (en) | 2011-04-15 | 2012-10-18 | Merck Patemt Gmbh | Anti- il-1r1 inhibitors for use in cancer |
| US9707272B2 (en) | 2011-07-12 | 2017-07-18 | Universitat Zurich | Method for the treatment of acne by administering IL-1β antibody |
| DE102011083595A1 (de) | 2011-09-28 | 2013-03-28 | Bayer Pharma AG | Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose |
| BR112014007253A2 (pt) * | 2011-09-30 | 2017-03-28 | Novartis Ag | uso de anticorpos que se ligam a il-1beta |
| AP2014007680A0 (en) | 2011-12-02 | 2014-06-30 | Novartis Ag | Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
| WO2013090635A2 (en) * | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
| WO2013087912A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| CN104144946A (zh) | 2011-12-19 | 2014-11-12 | 爱克索马美国有限责任公司 | 治疗痤疮的方法 |
| AR089529A1 (es) | 2011-12-30 | 2014-08-27 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 |
| EP3736289A1 (en) * | 2012-02-13 | 2020-11-11 | Agency For Science, Technology And Research | Il-beta neutralizing human monoclonal antibodies |
| CN103588878A (zh) * | 2012-08-15 | 2014-02-19 | 江苏泰康生物医药有限公司 | 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用 |
| TW201811825A (zh) | 2012-11-01 | 2018-04-01 | 美商艾伯維有限公司 | 抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途 |
| EP3750917A1 (en) * | 2012-11-05 | 2020-12-16 | Delenex Therapeutics AG | Binding members to il-1 beta |
| CA2891556A1 (en) | 2012-11-16 | 2014-05-22 | Novartis Ag | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
| EP4001307A1 (en) | 2012-12-17 | 2022-05-25 | Cell Medica Inc. | Antibodies against il-1 beta |
| CA2891686A1 (en) | 2012-12-18 | 2014-06-26 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
| MX2015013166A (es) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
| WO2015083120A1 (en) | 2013-12-04 | 2015-06-11 | Novartis Ag | USE OF IL-1β BINDING ANTIBODIES |
| WO2015198240A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
| EP3160990A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
| WO2016008851A1 (en) * | 2014-07-14 | 2016-01-21 | Boehringer Ingelheim International Gmbh | Anti-il-1b antibodies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| ES2952717T3 (es) | 2014-10-14 | 2023-11-03 | Novartis Ag | Moléculas de anticuerpos contra PD-L1 y usos de las mismas |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| KR20170082594A (ko) | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 사용 방법 |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| WO2016193931A1 (en) | 2015-06-04 | 2016-12-08 | Novartis Ag | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
| JP6878405B2 (ja) | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子を含む組み合わせ治療 |
| JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子およびその使用 |
| EP3426775A1 (en) | 2016-03-10 | 2019-01-16 | Novartis AG | Chemically modified messenger rna's |
| KR20190032436A (ko) | 2016-07-21 | 2019-03-27 | 노파르티스 아게 | 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 |
| JP2020513554A (ja) | 2016-12-07 | 2020-05-14 | プロジェニティ， インコーポレイテッド | 胃腸管の検出方法、装置およびシステム |
| CA3046093A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| AU2018287519B2 (en) | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| EP3655961A4 (en) * | 2017-07-17 | 2021-09-01 | Massachusetts Institute of Technology | HEALTHY AND SICK BARRIER TISSUE CELL ATLAS |
| WO2019038740A1 (en) | 2017-08-25 | 2019-02-28 | Novartis Ag | USE OF CANAKINUMAB |
| WO2019053591A1 (en) * | 2017-09-13 | 2019-03-21 | Novartis Ag | USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| BR112020022576A2 (pt) * | 2018-05-09 | 2021-02-09 | Novartis Ag | uso de canaquinumabe |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB2575853A (en) * | 2018-07-25 | 2020-01-29 | Robert Wotherspoon Hugh | IL-1ß binding antibody |
| CN110818793A (zh) | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| EP3878867A4 (en) * | 2018-11-07 | 2022-07-06 | Zeda Biopharmaceuticals, Inc. | Antibody binding to human il-1 ?, preparation method therefor and use thereof |
| CA3120619A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| GB201901187D0 (en) | 2019-01-29 | 2019-03-20 | Autolus Ltd | Treatment of neurotoxicity and/or cytokine release syndrome |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021062217A1 (en) * | 2019-09-26 | 2021-04-01 | Beth Israel Deaconess Medical Center, Inc. | Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm) |
| EP4073115A1 (en) | 2019-12-09 | 2022-10-19 | Novartis AG | Anti-interleukin 1 beta antibodies for treatment of sickle cell disease |
| EP4309722A3 (en) | 2019-12-13 | 2024-08-07 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| TWI793503B (zh) * | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | 抗IL-1β抗體 |
| EP4093430A4 (en) * | 2020-01-21 | 2024-01-24 | Tavotek Biotherapeutics (Hong Kong) Limited | AGENTS THAT DISRUPT IL-1BETA RECEPTOR SIGNALING |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2021257539A1 (en) * | 2020-06-16 | 2021-12-23 | Academia Sinica | ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
| JP2023549257A (ja) | 2020-11-18 | 2023-11-22 | ノバルティス アーゲー | Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体 |
| WO2022167916A1 (en) | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2022249040A1 (en) | 2021-05-24 | 2022-12-01 | Novartis Ag | Methods for the treatment of osteoarthritis |
| WO2022269451A1 (en) | 2021-06-22 | 2022-12-29 | Novartis Ag | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
| WO2025068957A1 (en) | 2023-09-29 | 2025-04-03 | Novartis Ag | Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations |
| GB202400340D0 (en) | 2024-01-10 | 2024-02-21 | Wotherspoon Hugh Robert | IL-1B binding antibody |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US534858A (en) * | 1895-02-26 | Workman s time-recorder | ||
| CA1172789A (en) | 1980-09-25 | 1984-08-14 | Hideo Kasahara | POLYMERIC MATERIAL COMPRISING A POLYAMIDE BONDED TO A COPOLYMER CONTAINING AN IMIDE OF AN .alpha.,.beta. UNSATURATED CARBOXYLIC ACID |
| US4772685A (en) | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP0364778B1 (en) | 1988-10-01 | 1996-03-13 | Otsuka Pharmaceutical Co., Ltd. | Antibody against interleukin-1beta |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
| US5429614A (en) | 1993-06-30 | 1995-07-04 | Baxter International Inc. | Drug delivery system |
| WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
-
2000
- 2000-08-22 GB GBGB0020685.4A patent/GB0020685D0/en not_active Ceased
-
2001
- 2001-08-16 PE PE2001000817A patent/PE20020319A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103946A patent/AR035581A1/es active IP Right Grant
- 2001-08-20 MX MXPA03001590A patent/MXPA03001590A/es active IP Right Grant
- 2001-08-20 BR BR0113420-5A patent/BR0113420A/pt not_active IP Right Cessation
- 2001-08-20 NZ NZ524199A patent/NZ524199A/en not_active IP Right Cessation
- 2001-08-20 KR KR1020087012282A patent/KR20080056316A/ko not_active Ceased
- 2001-08-20 AT AT01976118T patent/ATE396206T1/de active
- 2001-08-20 PT PT01976118T patent/PT1313769E/pt unknown
- 2001-08-20 CA CA2420231A patent/CA2420231C/en not_active Expired - Lifetime
- 2001-08-20 US US10/362,082 patent/US7446175B2/en not_active Expired - Lifetime
- 2001-08-20 EP EP01976118A patent/EP1313769B2/en not_active Expired - Lifetime
- 2001-08-20 KR KR1020037002161A patent/KR100910789B1/ko not_active Expired - Lifetime
- 2001-08-20 DK DK01976118.8T patent/DK1313769T4/da active
- 2001-08-20 JP JP2002521531A patent/JP4271936B2/ja not_active Expired - Lifetime
- 2001-08-20 SI SI200130844T patent/SI1313769T2/sl unknown
- 2001-08-20 SK SK213-2003A patent/SK288089B6/sk not_active IP Right Cessation
- 2001-08-20 CZ CZ2003-505A patent/CZ304470B6/cs not_active IP Right Cessation
- 2001-08-20 CN CNB018145140A patent/CN100547003C/zh not_active Expired - Lifetime
- 2001-08-20 PL PL360358A patent/PL212480B1/pl unknown
- 2001-08-20 NZ NZ534269A patent/NZ534269A/en not_active IP Right Cessation
- 2001-08-20 WO PCT/EP2001/009588 patent/WO2002016436A2/en not_active Ceased
- 2001-08-20 RU RU2003107564/13A patent/RU2286351C2/ru active Protection Beyond IP Right Term
- 2001-08-20 DE DE60134148T patent/DE60134148D1/de not_active Expired - Lifetime
- 2001-08-20 AU AU9549001A patent/AU9549001A/xx active Pending
- 2001-08-20 IL IL15446501A patent/IL154465A0/xx unknown
- 2001-08-20 ES ES01976118T patent/ES2305110T5/es not_active Expired - Lifetime
- 2001-08-20 DE DE122009000078C patent/DE122009000078I1/de active Pending
- 2001-08-20 AU AU2001295490A patent/AU2001295490B2/en not_active Expired
- 2001-08-20 HU HU0300806A patent/HU228159B1/hu active Protection Beyond IP Right Term
- 2001-08-21 MY MYPI20013927A patent/MY130248A/en unknown
- 2001-08-22 TW TW090120626A patent/TWI321568B/zh not_active IP Right Cessation
-
2003
- 2003-02-13 IL IL154465A patent/IL154465A/en active Protection Beyond IP Right Term
- 2003-02-17 ZA ZA200301275A patent/ZA200301275B/en unknown
- 2003-02-19 EC EC2003004490A patent/ECSP034490A/es unknown
- 2003-02-21 NO NO20030827A patent/NO332609B1/no not_active IP Right Cessation
-
2008
- 2008-08-01 JP JP2008199799A patent/JP2008295456A/ja active Pending
- 2008-08-11 CY CY20081100840T patent/CY1108779T1/el unknown
- 2008-09-26 US US12/238,502 patent/US7993878B2/en not_active Expired - Fee Related
-
2009
- 2009-11-24 NL NL300427C patent/NL300427I2/nl unknown
- 2009-11-25 LU LU91624C patent/LU91624I2/fr unknown
- 2009-11-30 BE BE2009C057C patent/BE2009C057I2/fr unknown
- 2009-12-03 FR FR09C0062C patent/FR09C0062I2/fr active Active
- 2009-12-09 CY CY2009019C patent/CY2009019I2/el unknown
-
2011
- 2011-06-29 US US13/171,631 patent/US8273350B2/en not_active Expired - Fee Related
-
2012
- 2012-11-21 NO NO2012018C patent/NO2012018I1/no unknown
-
2013
- 2013-04-26 HU HUS1300015C patent/HUS1300015I1/hu unknown
-
2017
- 2017-10-11 NO NO2017052C patent/NO2017052I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001295490B2 (en) | Antibodies to human IL-1beta | |
| EP1248804B1 (en) | Recombinant antibodies to human interleukin-1 beta | |
| AU2001295490A1 (en) | Antibodies to human IL-1beta | |
| HK1061403B (en) | ANTIBODIES TO HUMAN IL-1β |